Launching a virtual biotech is exhilarating—big science, big vision, lean teams, and high stakes.
But in the first 12 months, every decision matters: the wrong move in manufacturing, regulatory strategy, or vendor selection can create months of delay or millions in lost value.
For virtual sponsors—companies without their own labs, plants, or manufacturing sites—early planning across Chemistry, Manufacturing, and Controls (CMC) and regulatory strategy is the key to transforming a molecule into a viable development candidate.
Month 1–3: Laying the Scientific and Strategic Foundation
Here’s what the first year needs to focus on.
Key Actions:
- Define the molecule’s mechanism of action, target profile, and intended indication(s).
- Conduct feasibility assessments for formulation, manufacturability, and delivery.
- Develop a draft target product profile (TPP) with input from clinical, regulatory, and CMC experts.
Common Pitfalls:
- Assuming early R&D processes are scalable without technical validation
- Neglecting regulatory starting material definitions
- Delaying the engagement of CMC or regulatory consultants
Month 4–6: Building a Phase-Appropriate CMC Plan
Key Actions:
- Select and qualify CDMOs for drug substance and drug product manufacturing.
- Finalize early synthetic route or production process with regulatory starting material justification.
- Initiate early analytical method development with an eye toward validation later.
- Conduct stability-indicating studies to define clinical shelf-life expectations.
Common Pitfalls:
- Choosing a CDMO based solely on cost without evaluating technical/regulatory expertise
- Overlooking the need for a phase-appropriate (but credible) CMC package for IND submission
Month 7–9: Preparing for Regulatory Engagement
Key Actions:
- Plan and request early FDA meetings (e.g., INTERACT, pre-IND) if warranted.
- Prepare initial briefing documents highlighting clinical, nonclinical, and CMC strategies.
- Assemble and organize preliminary regulatory documentation and data.
Common Pitfalls:
- Underpreparing CMC content for FDA meetings
- Failing to address potential agency questions about supply chain, manufacturing readiness, and stability data
Month 10–12: Positioning for IND Readiness and Early Clinical Development
Key Actions:
- Finalize IND-enabling studies and compile CMC sections of the IND in CTD format.
- Secure drug supply for initial clinical trials, including clear GMP certification documentation.
- Confirm that vendor quality systems and documentation meet regulatory expectations.
- Begin strategic planning for Phase 2/3 scalability and validation needs—even before Phase 1 data.
Common Pitfalls:
- Treating the IND as a “one-and-done” document rather than the start of long-term regulatory relationships
- Assuming Phase 1 success automatically means Phase 2/3 readiness
Early Success Metrics for Virtual Sponsors
| Goal | Metric of Success |
| CMC Readiness | Phase-appropriate data package prepared for IND filing |
| Regulatory Strategy | Clear documentation of regulatory pathways and agency feedback |
| Vendor Management | Qualified CDMOs/CROs with quality agreements in place |
| Clinical Supply Chain | GMP drug supply secured and traceable for clinical trials |
| Organizational Scalability | Systems for documentation, decision-making, and regulatory interactions established |
Final Thoughts
In the early life of a virtual biotech, it’s easy to get caught up in the science alone.
But a disciplined, proactive CMC and regulatory strategy is what turns great science into real-world products.
At DSI, we specialize in helping virtual sponsors create strong foundations from day one—building strategies that anticipate the next milestone, not just react to it. If you’re launching or scaling a virtual biotech, we can help you move from molecule to market with confidence.
